Team

Team.jpg

Prof Jacqui Shaw  - Director

Professor Jacqui Shaw undertook a PhD in Molecular Genetics at Imperial College. After her completing her first post-doctoral post she came to Leicester in 1993 to a Lectureship in Molecular Pathology. She was appointed as Professor of Translational Cancer Genetics in 2013. Professor Shaw’s research is focused on circulating nucleic acids for early detection and monitoring of breast and lung cancers. In collaboration with Prof RC Coombes at Imperial College, she leads an integrated programme of clinical and translational research between the two universities funded by a Programme award from Cancer Research UK. She also works with Professor Charlie Swanton as part of the TRACERx major national trial analysing genetic changes in the tumours of non-small cell lung cancer patients from diagnosis and through their treatment. Professor Shaw also leads the cfDNA advisory group for the 100,000 Genomes project led by Genomics England and sits on a number of advisory boards and editorial boards of international scientific journals.

Find out more

Dr Ruth Barber - Deputy Director

Ruth joined the LD3 in 2011. From 2011 to 2014 Ruth provided practical support to a number of successful LD3 research projects including two developing novel therapies for the treatment of blood cancers, focusing primarily on the in cellulo and in vivo validation and testing of novel compounds. Since 2014 Ruth has taken on a more managerial role with the LD3 team, she has been instrumental in the acquisition of significant translational research income from the MRC Confidence in Concept Award scheme (~£2.3 M to date) which has been used to support ~40 internal projects and in growing the LD3 team to the current group of six talented researchers.

Find out more

Dr. Christine Alberti-Segui -  Research Manager

Christine joined LD3 in September 2018 and provides strong expertise in the development of molecular diagnostic tests, from feasibility to product validation, regulatory submission and product launch. She has past experience in microbial genetics, with a focus on host-pathogen interaction. As the new LD3 manager, Christine is responsible for the management of the team and the management of the LD3 project portfolio.

Find out more

Dr Karen Bowman - Research Associate

Karen joined LD3 in March 2015 and is expert in cell-based assay compound screening, DNA damage and repair and in vitro, cellular and ex vivo assay development. Karen was part of the pre-clinical discovery team at the University of Newcastle upon Tyne to discover and develop the anti-cancer agent Rucaparib (brand name Rubraca®  commercialised by Clovis Oncology) a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1 (PARP-1). Karen project manages LD3 supported projects over multiple therapeutic areas such as cardiovascular disease, diabetes, oncology, and lung disease.

Find out more

Dr Li-Ying Lin - Research Associate

Li-Ying joined LD3 in 2014 and have been involved in several Oncology projects. Her work is focused on providing high level technical expertise and knowledge for structure-based drug design within LD3. Li-Ying has participated in early drug discovery projects collaborating with drug discovery companies, such as GSK, LifeArc, AstraZeneca and Domainex, by offering the information of complex atomic structures of drug-like compounds and proteins which are involved in development of cancer and disease.

Find out more

Dr Sian Evans - Research Associate

Sian joined the LD3 team in 2015 with the aim to drive a Discovery Fast Track Challenge programme in collaboration with GlaxoSmithKline (GSK), which has since developed successfully into a Discovery Partnerships with Academia (DPAc) award. Sian is primarily responsible for the cell based assays and compound management carried out within the DPAc here at Leicester.

Find out more

Dr Susann Lehmann - Research Associate

Susann joined LD3 in January 2017 and provides extensive expertise in molecular biology and in in-vitro and cellular assay development. Since starting with LD3, Susann has worked on multiple translational projects in various research backgrounds. These include developing a mitochondrial reporter assay for compound testing in Parkinson’s disease cell culture models, to validating a cancer diagnostics test using tNGS to validating binding of murine ligands to an engineered ligand trap protein for future testing in pre-clinical models of vascular inflammation. Susann is also currently supporting the Leicester Molecular Diagnostics lab in implementing ISO15189:2012 accreditation for their cancer diagnostic testing workflows.

Find out more

Carolyn Jones - Research Assistant

Carolyn joined LD3 in May 2018, and is currently supporting an oncology project to validate a cancer diagnostics test using tNGS. Carolyn has extensive industry background with AstraZeneca, and a variety of lab experience involving molecular biology and genomics techniques.

Mrs Jennifer Schofield - Senior Research Technician

Jenny joined LD3 in April 2018, and is currently supporting an oncology project: Discovery Partnerships with Academia (DPAc) in collaboration with GlaxoSmithKline (GSK) . Jenny has a variety of technical lab experience, having worked in various departments at University of Leicester since 1994.

Discover:

Share this page:

Contact us

LD3 Research Manager, 

Dr. Christine Alberti-Segui:

+44 (0) 116 252 5174

LD3 Office:

+44 (0) 116 252 3342              

drugdiscovery@le.ac.uk 

Contact Details

College of Life Sciences
University of Leicester
Maurice Shock Building
University Road
Leicester
LE1 7RH